Downloads: 5 | Views: 91 | Weekly Hits: ⮙2 | Monthly Hits: ⮙5
Review Papers | Medicine | India | Volume 13 Issue 4, April 2024 | Popularity: 5 / 10
SGLT2 and GLP - 1 Inhibitors: Enlightening their Role beyond their Glucose Lowering Properties
Geetanjali Mehra
Abstract: Cardiovascular illnesses continue to be the top cause of death among type 2 diabetics. There have been numerous advancements for treatment of kidney disease associated with diabetes during last five years. Glucagon-like peptide-1 receptor and sodium-glucose cotransporter-2 inhibitors were originally utilised in glycaemic control, but research has demonstrated that their profits also extend to cardiac and renal outcomes. There is a high hazard of heart disease and chronic kidney disease, type 2 diabetes care today involves a increase in the medication for the control of different health issues caused by diabetes. In this paper we discuss the rationale for using SGLT2 inhibitors and GLP-1 in patients with type 2 diabetes in combination manner to preserve the heart and kidneys. SGLT-2 and GLP-1 inhibitors have diverse roles in apart from glucose lowering properties that helps to reduce the side effects. Patients with non-diabetic kidney disease may advantage from these medicines as well. Hypertension, Body weight, and inflammation are all prevalent variables for kidney disease, regardless of whether or not diabetes is present.
Keywords: SGLT-2 inhibitors, GLP-1 inhibitors, Cardiovascular, Glucose-lowering agents
Edition: Volume 13 Issue 4, April 2024
Pages: 709 - 714